The Desmin (DES) Mutation p.A337P Is Associated with Left-Ventricular Non-Compaction Cardiomyopathy.
Olga V KulikovaAndreas BrodehlAnna Vitalievna KiselevaRoman P MyasnikovAlexey Nikolaevich MeshkovCaroline StanasiukAnna GärtnerMikhail G DivashukEvgeniia Andreevna SotnikovaSergey KoretskiyAnastasia Alexandrovna ZharikovaViktoria KozlovaElena A MershinaPolina PilusValentin E SinitsynHendrik MiltingSergey BoytsovOksana M DrapkinaPublished in: Genes (2021)
Here, we present a small Russian family, where the index patient received a diagnosis of left-ventricular non-compaction cardiomyopathy (LVNC) in combination with a skeletal myopathy. Clinical follow-up analysis revealed a LVNC phenotype also in her son. Therefore, we applied a broad next-generation sequencing gene panel approach for the identification of the underlying mutation. Interestingly, DES-p.A337P was identified in the genomes of both patients, whereas only the index patient carried DSP-p.L1348X. DES encodes the muscle-specific intermediate filament protein desmin and DSP encodes desmoplakin, which is a cytolinker protein connecting desmosomes with the intermediate filaments. Because the majority of DES mutations cause severe filament assembly defects and because this mutation was found in both affected patients, we analyzed this DES mutation in vitro by cell transfection experiments in combination with confocal microscopy. Of note, desmin-p.A337P forms cytoplasmic aggregates in transfected SW-13 cells and in cardiomyocytes derived from induced pluripotent stem cells underlining its pathogenicity. In conclusion, we suggest including the DES gene in the genetic analysis for LVNC patients in the future, especially if clinical involvement of the skeletal muscle is present.
Keyphrases
- end stage renal disease
- left ventricular
- ejection fraction
- heart failure
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- copy number
- escherichia coli
- gene expression
- transcription factor
- metabolic syndrome
- bone marrow
- small molecule
- oxidative stress
- acute coronary syndrome
- early onset
- patient reported
- binding protein
- drug induced